Literature DB >> 21605155

Serum myostatin levels and grip strength in normal subjects and patients on maintenance haemodialysis.

Der-Sheng Han1, Yung-Ming Chen, Sen-Yung Lin, Hao-Hsiang Chang, Tao-Min Huang, Yu-Chiao Chi, Wei-Shiung Yang.   

Abstract

OBJECTIVE: Myostatin, a negative regulator of skeletal muscle growth, may modulate grip strength, an indicator of muscle function. Its serum levels could be modulated by maintenance haemodialysis (MHD).
DESIGN: A descriptive cross-sectional study. PATIENTS: Forty-one normal controls and 60 MHD patients using different dialyzers at a medical centre. MEASUREMENTS: The grip strength of the dominant hand, body composition, and the predialysis and postdialysis serum myostatin and IGF-1 levels were measured.
RESULTS: The MHD patients had lower body mass index, IGF-1 level, and grip strength than the normal controls. The patients using the high-flux dialyzer had better grip strength than those using the low-flux dialyzer (25·5 vs 19·2 kg). The predialysis myostatin level was higher in low-flux dialyzer than high-flux dialyzer (31·0 vs 18·5 μg/ml). Interestingly, the high-flux dialyzer reduced the serum myostatin by 36%, whereas low-flux dialyzer increased it by 25%. The myostatin was inversely related to age and the use of high-flux dialyzer. Furthermore, the grip strength was negatively related to age, female gender, muscle mass, myostatin levels and haemodialysis, but positively to the use of high-flux dialyzer in linear regression. The risk of low grip strength was 7·6 times higher in those with higher serum myostatin with the adjustment of age, gender, muscle mass, haemodialysis and mode of dialysis in a logistic regression.
CONCLUSIONS: The mode of dialyzer modulates the blood levels of myostatin. Higher myostatin is associated with lower muscle function. The use of myostatin assay in various clinical settings merits further investigation.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21605155     DOI: 10.1111/j.1365-2265.2011.04120.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  30 in total

Review 1.  Therapies for musculoskeletal disease: can we treat two birds with one stone?

Authors:  Christian M Girgis; Nancy Mokbel; Douglas J Digirolamo
Journal:  Curr Osteoporos Rep       Date:  2014-06       Impact factor: 5.096

Review 2.  Myostatin--the holy grail for muscle, bone, and fat?

Authors:  B Buehring; N Binkley
Journal:  Curr Osteoporos Rep       Date:  2013-12       Impact factor: 5.096

Review 3.  Bone is Not Alone: the Effects of Skeletal Muscle Dysfunction in Chronic Kidney Disease.

Authors:  Keith G Avin; Ranjani N Moorthi
Journal:  Curr Osteoporos Rep       Date:  2015-06       Impact factor: 5.096

Review 4.  Managing Musculoskeletal and Kidney Aging: A Call for Holistic Insights.

Authors:  Pierre-Emmanuel Cailleaux; Martine Cohen-Solal
Journal:  Clin Interv Aging       Date:  2022-05-04       Impact factor: 3.829

Review 5.  New insights about the putative role of myokines in the context of cardiac rehabilitation and secondary cardiovascular prevention.

Authors:  Domenico Di Raimondo; Giuseppe Miceli; Gaia Musiari; Antonino Tuttolomondo; Antonio Pinto
Journal:  Ann Transl Med       Date:  2017-08

Review 6.  The Vicious Cycle of Myostatin Signaling in Sarcopenic Obesity: Myostatin Role in Skeletal Muscle Growth, Insulin Signaling and Implications for Clinical Trials.

Authors:  L A Consitt; B C Clark
Journal:  J Frailty Aging       Date:  2018

7.  Myostatin as a mediator of sarcopenia versus homeostatic regulator of muscle mass: insights using a new mass spectrometry-based assay.

Authors:  H Robert Bergen; Joshua N Farr; Patrick M Vanderboom; Elizabeth J Atkinson; Thomas A White; Ravinder J Singh; Sundeep Khosla; Nathan K LeBrasseur
Journal:  Skelet Muscle       Date:  2015-07-15       Impact factor: 4.912

8.  Serum myostatin is reduced in individuals with metabolic syndrome.

Authors:  Der-Sheng Han; Yu Chu-Su; Chih-Kang Chiang; Fen-Yu Tseng; Ping-Huei Tseng; Chi-Ling Chen; Kwan-Dun Wu; Wei-Shiung Yang
Journal:  PLoS One       Date:  2014-09-25       Impact factor: 3.240

9.  Association of the Myostatin gene with obesity, abdominal obesity and low lean body mass and in non-diabetic Asian Indians in north India.

Authors:  Surya Prakash Bhatt; Priyanka Nigam; Anoop Misra; Randeep Guleria; Kalpana Luthra; S K Jain; M A Qadar Pasha
Journal:  PLoS One       Date:  2012-08-20       Impact factor: 3.240

10.  Myostatin and insulin-like growth factor I: potential therapeutic biomarkers for pompe disease.

Authors:  Yin-Hsiu Chien; Der-Sheng Han; Wuh-Liang Hwu; Beth L Thurberg; Wei-Shiung Yang
Journal:  PLoS One       Date:  2013-08-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.